A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)

A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)

Abstract Background In preclinical models, recombinant human relaxin-2 (serelaxin) had anti-fibrotic effects and ameliorated portal hypertension (PH). A small exploratory study in patients with cirrhosis also suggested that serelaxin could reduce portal pressure. Methods In a phase 2, double-blind,...

Full description

Bibliographic Details
Main Authors: Fiona J. Gifford, Philip D. J. Dunne, Graeme Weir, Hamish Ireland, Catriona Graham, Sharon Tuck, Peter C. Hayes, Jonathan A. Fallowfield
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Trials
Subjects:
Cirrhosis
Portal hypertension
Serelaxin
Online Access:http://link.springer.com/article/10.1186/s13063-020-4203-9

Internet

http://link.springer.com/article/10.1186/s13063-020-4203-9

Similar Items